A Pediatric Phase 1 Trial Of Vorinostat And Temozolomide In Relapsed Or Refractory Primary Brain Or Spinal Cord Tumors: A Children’s Oncology Group Phase 1 Consortium Study

PURPOSE: We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hummel, Trent R., Wagner, Lars, Ahern, Charlotte, Fouladi, Maryam, Reid, Joel M., McGovern, Renee M., Ames, Matthew M., Gilbertson, Richard J., Horton, Terzah, Ingle, Ashish M., Weigel, Brenda, Blaney, Susan M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4139006/
https://ncbi.nlm.nih.gov/pubmed/23554030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24541
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge